Dermatophagoides pteronyssinus allergens (Der p)

Dermatophagoides pteronyssinus allergens are a group of proteins derived from the European house dust mite that serve as potent triggers for Type I hypersensitivity reactions (WHO/IUIS Allergen Nomenclature Sub-Committee, allergen.org). The most clinically significant components include Der p 1, a cysteine protease, and Der p 2, a lipid-binding protein, which together account for the majority of IgE reactivity in sensitized individuals (Thomas et al., 2010, PMID: 20377508). These allergens interact with the human immune system by cross-linking IgE on mast cells and basophils, leading to the release of inflammatory mediators such as histamine and leukotrienes (Galli et al., 2008, PMID: 18449189). This process results in the clinical manifestations of allergic rhinitis, allergic asthma, and atopic dermatitis (Calderon et al., 2015, PMID: 25864773). In a therapeutic context, standardized extracts of these allergens are used in allergen-specific immunotherapy (AIT) to desensitize patients (FDA, Odactra Prescribing Information). AIT aims to modify the underlying disease by inducing peripheral T-cell tolerance and promoting the production of protective IgG4 antibodies (Akdis & Akdis, 2014, PMID: 24943125). This modulation reduces the clinical severity of allergic diseases upon subsequent natural exposure to the mites. Modern treatments like sublingual immunotherapy (SLIT) tablets provide a standardized dose of these allergens to achieve long-term clinical benefits and disease modification (Durham & Penagos, 2016, PMID: 27130010).

Other names

House dust mite allergensHDM allergensEuropean house dust mite allergensDer p allergens

Allergen-specific immunotherapy (AIT) induces immune tolerance by shifting the immune response from a Th2-dominated profile to a Th1 and regulatory T-cell (Treg) profile. This leads to the production of IL-10 and TGF-beta, which suppress allergic inflammation and induce the production of allergen-specific IgG4 antibodies that compete with IgE for allergen binding, thereby preventing mast cell degranulation (Akdis & Akdis, 2014, PMID: 24943125).